melatonin has been researched along with Coronary Disease in 21 studies
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk." | 9.30 | Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. ( Asemi, Z; Bahmani, F; Ostadmohammadi, V; Raygan, F; Reiter, RJ, 2019) |
| " The aim of this study was to determine the association between urinary 6-sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes." | 8.02 | Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes. ( Maiko, H; Mori, H; Okada, Y; Tanaka, K; Tanaka, Y, 2021) |
| "The study included 2 groups of patients with arterial hypertension and coronary heart disease treated by traditional therapy or its combination with melatonin." | 7.77 | [Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin]. ( , 2011) |
| " melatonin (4 + 4 mg/kg, after induction of ischemia and at reperfusion onset) administered either alone or in combination with the thrombolytic tissue-plasminogen activator (t-PA, 10 mg/kg), on cerebral laser Doppler flow (LDF) and ischemic injury were studied after 30 min of middle cerebral artery (MCA) thread occlusion in male C57BL/6 mice." | 7.72 | Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. ( Hermann, DM; Kilic, E; Kilic, U; Reiter, RJ; Yulug, B, 2004) |
| "The observation of raised nocturnal urinary norepinephrine excretion in patients with coronary heart disease (CHD), together with results of animal experiments showing a suppression of sympathetic activity by melatonin, were the reasons for this investigation." | 7.69 | [Melatonin and coronary heart disease]. ( Brugger, P; Herold, M; Marktl, W, 1997) |
| "Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk." | 5.30 | Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. ( Asemi, Z; Bahmani, F; Ostadmohammadi, V; Raygan, F; Reiter, RJ, 2019) |
| "Melatonin was significantly lower in the patients than in 10 healthy controls (median 7." | 5.29 | Impaired nocturnal secretion of melatonin in coronary heart disease. ( Brugger, P; Herold, M; Marktl, W, 1995) |
| " The aim of this study was to determine the association between urinary 6-sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes." | 4.02 | Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes. ( Maiko, H; Mori, H; Okada, Y; Tanaka, K; Tanaka, Y, 2021) |
| "The study included 2 groups of patients with arterial hypertension and coronary heart disease treated by traditional therapy or its combination with melatonin." | 3.77 | [Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin]. ( , 2011) |
| " melatonin (4 + 4 mg/kg, after induction of ischemia and at reperfusion onset) administered either alone or in combination with the thrombolytic tissue-plasminogen activator (t-PA, 10 mg/kg), on cerebral laser Doppler flow (LDF) and ischemic injury were studied after 30 min of middle cerebral artery (MCA) thread occlusion in male C57BL/6 mice." | 3.72 | Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. ( Hermann, DM; Kilic, E; Kilic, U; Reiter, RJ; Yulug, B, 2004) |
| " One measurable variable of the ageing process may be melatonin, known to decrease with age and to be lower in patients with coronary heart disease than in normal individuals." | 3.69 | Premature ageing: the link between psychosocial risk factors and disease. ( Nilsson, PM, 1996) |
| "The observation of raised nocturnal urinary norepinephrine excretion in patients with coronary heart disease (CHD), together with results of animal experiments showing a suppression of sympathetic activity by melatonin, were the reasons for this investigation." | 3.69 | [Melatonin and coronary heart disease]. ( Brugger, P; Herold, M; Marktl, W, 1997) |
| "The current study revealed that ML and NAC are potent antioxidants with similar efficacy in terms of reducing CABG related cardiac injury and oxidative stress with the dosage employed for the intervention." | 2.87 | Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial. ( Akbarzadeh, S; Anvaripour, A; Bahtoei, M; Iranpour, D; Movahed, A; Netticadan, T; Ostovar, A; Raj, P; Shafiei, E; Shahryari, H; Tahmasebi, R, 2018) |
| "Melatonin levels were measured with a commercially available radioimmunoassay kit." | 1.32 | Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. ( Aktoz, M; Altun, A; Ciftci, S; Ozbay, G; Vardar, A; Yaprak, M, 2003) |
| "Melatonin was significantly lower in the patients than in 10 healthy controls (median 7." | 1.29 | Impaired nocturnal secretion of melatonin in coronary heart disease. ( Brugger, P; Herold, M; Marktl, W, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, K | 1 |
| Okada, Y | 1 |
| Maiko, H | 1 |
| Mori, H | 1 |
| Tanaka, Y | 1 |
| Raygan, F | 1 |
| Ostadmohammadi, V | 1 |
| Bahmani, F | 1 |
| Reiter, RJ | 2 |
| Asemi, Z | 1 |
| Shafiei, E | 1 |
| Bahtoei, M | 1 |
| Raj, P | 1 |
| Ostovar, A | 1 |
| Iranpour, D | 1 |
| Akbarzadeh, S | 1 |
| Shahryari, H | 1 |
| Anvaripour, A | 1 |
| Tahmasebi, R | 1 |
| Netticadan, T | 1 |
| Movahed, A | 1 |
| Dwaich, KH | 1 |
| Al-Amran, FG | 1 |
| Al-Sheibani, BI | 1 |
| Al-Aubaidy, HA | 1 |
| Opie, LH | 1 |
| Lecour, S | 1 |
| Rapoport, SI | 3 |
| Breus, TK | 2 |
| Gerber, AM | 1 |
| Oosthuizen, GM | 1 |
| Crous, A | 1 |
| Yaprak, M | 1 |
| Altun, A | 1 |
| Vardar, A | 1 |
| Aktoz, M | 1 |
| Ciftci, S | 1 |
| Ozbay, G | 1 |
| Guo, XY | 1 |
| Luo, AL | 1 |
| Ren, HZ | 1 |
| Yie, TH | 1 |
| Huang, YG | 1 |
| Kilic, E | 1 |
| Kilic, U | 1 |
| Yulug, B | 1 |
| Hermann, DM | 1 |
| Nagtegaal, E | 1 |
| Smits, M | 1 |
| Swart, W | 1 |
| van der Meer, G | 1 |
| Kerkhof, G | 1 |
| Brugger, P | 2 |
| Marktl, W | 2 |
| Herold, M | 2 |
| Nilsson, PM | 1 |
| Malinovskaia, NK | 1 |
| Oraevskií, VN | 1 |
| Komarov, FI | 1 |
| Nosovskií, AM | 1 |
| Vetterberg, L | 1 |
| Maurizi, CP | 1 |
| Girotti, L | 1 |
| Lago, M | 1 |
| Ianovsky, O | 1 |
| Carbajales, J | 1 |
| Elizari, MV | 1 |
| Brusco, LI | 1 |
| Cardinali, DP | 1 |
| Malaia, LT | 1 |
| Rachinskiĭ, ID | 2 |
| Shushliapin, OI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation[NCT04547439] | Phase 2 | 36 participants (Anticipated) | Interventional | 2021-02-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for melatonin and Coronary Disease
| Article | Year |
|---|---|
Melatonin has multiorgan effects.
Topics: Animals; Antioxidants; Coronary Disease; Humans; Melatonin | 2016 |
[Melatonin as a most important factor of natural electromagnetic fields impacting patients with hypertensive disease and coronary heart disease. Part 1].
Topics: Circadian Rhythm; Coronary Disease; Electromagnetic Fields; Humans; Hypertension; Melatonin | 2011 |
[Melatonin as a most important factor in the action of weak natural magnetic fields on patients with hypertensive disease and coronary heart disease. Part 2].
Topics: Animals; Atmospheric Pressure; Circadian Rhythm; Coronary Disease; Electromagnetic Fields; Humans; H | 2011 |
3 trials available for melatonin and Coronary Disease
15 other studies available for melatonin and Coronary Disease
| Article | Year |
|---|---|
Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.
Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; F | 2021 |
[Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Therapy, Combination; F | 2011 |
A possible link between melatonin levels, stress and coronary heart disease.
Topics: Causality; Circadian Rhythm; Coronary Disease; Disease Progression; Humans; Inflammation; Interleuki | 2002 |
Decreased nocturnal synthesis of melatonin in patients with coronary artery disease.
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; Circadian Rhythm; Coronary Disease; Humans; | 2003 |
[Perioperative melatonin secretion rhyme in patients undergoing coronary artery bypass grafting surgery].
Topics: Cardiopulmonary Bypass; Circadian Rhythm; Coronary Artery Bypass; Coronary Disease; Humans; Hydrocor | 2003 |
Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator.
Topics: Animals; Brain Ischemia; Caspase 3; Caspase Inhibitors; Cell Death; Coronary Disease; Corpus Striatu | 2004 |
Melatonin secretion and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Circadian Rhythm; Coronary Disease; Humans; Light; Melatonin; Sleep | 1995 |
Impaired nocturnal secretion of melatonin in coronary heart disease.
Topics: Circadian Rhythm; Coronary Disease; Female; Humans; Male; Melatonin; Middle Aged; Radioimmunoassay; | 1995 |
Premature ageing: the link between psychosocial risk factors and disease.
Topics: Aging; Chronic Disease; Coronary Disease; Health Status; Humans; Life Style; Melatonin; Models, Theo | 1996 |
[Effects of disturbances of natural magnetic field of the Earth on melatonin production in patients with coronary heart disease].
Topics: Aged; Circadian Rhythm; Coronary Disease; Earth, Planet; Female; Humans; Magnetics; Male; Melatonin; | 1997 |
[Melatonin and coronary heart disease].
Topics: Circadian Rhythm; Coronary Disease; Female; Humans; Male; Melatonin; Middle Aged; Pineal Gland; Refe | 1997 |
Short note: The fetal origins hypothesis: linking pineal gland hypoplasia with coronary heart disease and stroke.
Topics: Cerebrovascular Disorders; Coronary Disease; Female; Humans; Infant, Newborn; Melatonin; Pineal Glan | 1998 |
Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Aging; Coronary Disease; Female; Humans; Male; Melatonin; Middle Age | 2000 |
[State of the neurohumoral regulatory system in circulatory insufficiency].
Topics: 17-Ketosteroids; Adult; Aged; Aldosterone; Angiotensinogen; Coronary Disease; Cortisone; Endopeptida | 1976 |
[Disordered melatonin metabolism in chronic circulatory insufficiency].
Topics: Aged; Arrhythmias, Cardiac; Cardiovascular Diseases; Chronic Disease; Coronary Disease; Humans; Hype | 1978 |